Published in Am J Med on May 01, 2003
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood (2013) 1.16
Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am (2013) 1.10
Heparin-induced thrombocytopenia. Annu Rev Med (2010) 0.95
Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. J Thromb Thrombolysis (2008) 0.82
Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica (2011) 0.80
Improving the laboratory diagnosis of heparin-induced thrombocytopenia. Am J Med (2003) 0.76
The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med (2016) 0.75
Rapid diagnosis of heparin-induced thrombocytopenia using a particle gel immunoassay in at-risk cardiac surgery patients. Asian J Transfus Sci (2013) 0.75
Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood (2009) 3.18
von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood (2010) 2.82
Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med (2003) 2.76
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood (2012) 1.87
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood (2004) 1.67
Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. Thromb Haemost (2008) 1.50
Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic event. Thromb Haemost (2009) 1.48
Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood (2014) 1.47
Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus. Transfusion (2004) 1.45
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica (2007) 1.39
Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood (2002) 1.29
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood (2005) 1.27
Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion (2012) 1.27
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood (2004) 1.20
C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med (2002) 1.14
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood (2013) 1.13
Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion (2009) 1.09
Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion (2008) 1.07
Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med (2014) 1.02
Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis (2002) 0.99
Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? Thromb Haemost (2005) 0.99
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica (2011) 0.99
Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res (2002) 0.98
ADAMTS13 activity in sickle cell disease. Am J Hematol (2006) 0.95
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol (2003) 0.92
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol (2010) 0.92
von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol (2004) 0.92
D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis (2009) 0.92
Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion (2009) 0.92
Platelets: thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2002) 0.91
Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol (2012) 0.91
Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis (2009) 0.91
Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion (2011) 0.90
The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis (2013) 0.90
Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med (2012) 0.88
The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection. Eur J Haematol (2008) 0.87
A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost (2006) 0.86
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood (2008) 0.86
Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica (2008) 0.86
Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood (2004) 0.86
Contact system activation in human sepsis - 47kD HK, a marker of sepsis severity? Swiss Med Wkly (2008) 0.85
Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost (2004) 0.85
Prospective, paired crossover comparison of multiple, single-needle plateletpheresis procedures with the Amicus and Trima Accel cell separators. Transfusion (2006) 0.85
A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. Ann Hematol (2008) 0.85
Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol (2004) 0.84
Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thromb Haemost (2007) 0.84
Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol (2008) 0.84
A KEL gene encoding serine at position 193 of the Kell glycoprotein results in expression of KEL1 antigen. Transfusion (2006) 0.82
Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly (2007) 0.81
Factor XIII in severe sepsis and septic shock. Thromb Res (2006) 0.81
Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb Res (2002) 0.81
Severe transfusion-related acute lung injury. Anesth Analg (2005) 0.80
Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+). J Thromb Thrombolysis (2013) 0.80
Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica (2004) 0.80
Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica (2011) 0.80
Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. Swiss Med Wkly (2002) 0.79
Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiency. Transfusion (2006) 0.78
Platelet Recruitment during Multiple Donor Platelet Apheresis Differs between Cell Separators. Transfus Med Hemother (2011) 0.78
Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2012) 0.78
Hemostatic risk factors in ischemic stroke. Thromb Haemost (2003) 0.78
Depressive symptoms, perceived social support, and prothrombotic measures in patients with venous thromboembolism. Thromb Res (2012) 0.77
Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: another case of factor IX propeptide mutation. Thromb Haemost (2011) 0.77
Swiss Haemovigilance Data and Implementation of Measures for the Prevention of Transfusion Associated Acute Lung Injury (TRALI). Transfus Med Hemother (2008) 0.77
Rumpel-Leede sign in thrombocytopenia due to Epstein-Barr virus-induced mononucleosis. Br J Haematol (2009) 0.77
Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. Semin Thromb Hemost (2002) 0.77
The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential. Leuk Res (2012) 0.76
Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired alpha2-antiplasmin deficiency associated with AL amyloidosis. Thromb Haemost (2009) 0.76
Hemophilia A pseudoaneurysm in a patient with high responding inhibitors complicating total knee arthroplasty: embolization: a cost-reducing alternative to medical therapy. Cardiovasc Intervent Radiol (2006) 0.76
The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Pathophysiol Haemost Thromb (2005) 0.76
On the dosing of lepirudin. Br J Clin Pharmacol (2011) 0.75
Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. Blood (2003) 0.75
Prospective, Paired Crossover Comparison of the in vitro Quality of Red Blood Cells Collected by the Automate for Blood Collection Device or by a Conventional Method. Transfus Med Hemother (2009) 0.75
Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review. Thromb Haemost (2016) 0.75
Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease. Blood Coagul Fibrinolysis (2003) 0.75
Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis. Cytometry B Clin Cytom (2014) 0.75
Transfusion medicine illustrated. Pica, peanuts, and plasma exchange. Transfusion (2006) 0.75
Recruitment of platelets, white blood cells, and hematopoietic progenitor cells during high-yield plateletpheresis. Transfusion (2011) 0.75
Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene. Eur J Haematol (2013) 0.75
The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. Thromb Haemost (2014) 0.75
May-Thurner syndrome: missed diagnosis and missed early treatment? Hamostaseologie (2017) 0.75
Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients. Swiss Med Wkly (2011) 0.75
Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. Br J Haematol (2008) 0.75
Independent association of sleep quality, fatigue, and vital exhaustion with platelet count in patients with a previous venous thromboembolic event. Platelets (2009) 0.75
Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation. Thromb Haemost (2017) 0.75
[Thrombotic thrombocytopenic purpura--an often missed diagnosis]. Rev Med Suisse (2014) 0.75